Home
Conditions
Neuroendocrine Tumors

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,767 public trials 494 recruiting studies

Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Active, Not Recruiting

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

NCT03311308

Conditions: Advanced Melanoma, Melanoma, Neoplasms, +10 more
Locations: Univ of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT03025256

Conditions: Acral Lentiginous Melanoma, Bronchial Neoplasms, Carcinoma, Bronchogenic, +37 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

NCT04356729

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Neoplasms, +13 more
Locations: Dana Farber Cancer Institute Boston, Massachusetts, United States

Massachusetts General Hospital Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)

NCT05520099

Conditions: Adenocarcinoma, Bladder Cancer, Bronchial Neoplasms, +72 more
Locations: CARTI Cancer Center Little Rock, Arkansas, United States

Salinas Valley Memorial Healthcare System Salinas, California, United States

AdventHealth Orlando Orlando, Florida, United States

Memorial Health System Pembroke Pines, Florida, United States

View Trial Details

Active, Not Recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

NCT00539591

Conditions: Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations: Rady Children's Hospital San Diego, California, United States

St. Jude Children's Research Hospital Memphis, Tennessee, United States

The Children's Cancer Hospital at UT M.D. Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

NCT03175432

Conditions: BRAF V600 Wild Type, Brain Diseases, Brain Neoplasms, +22 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

NCT06790706

Conditions: Adenocarcinoma, Anaplastic Thyroid Carcinomas, Carcinoid Tumor, +27 more
Locations: Institut de Cancerologie de l'Ouest , medical oncology department Angers, France

Institut Bergonié, medical oncology department Bordeaux, France

Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital Bron, France

Centre Hospitalier Universitaire de Lille, medical oncology department Lille, France

View all 15 locations

View Trial Details

Active, Not Recruiting

The French E3N Prospective Cohort Study

NCT03285230

Conditions: Asthma, Basal Ganglia Diseases, Behavior, +72 more
Locations: Villejuif, France

View Trial Details

Active, Not Recruiting

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

NCT03131908

Conditions: Melanoma, Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma, +11 more
Locations: University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations: Local Institution - 0088 Birmingham, Alabama, United States

Local Institution - 0126 Tucson, Arizona, United States

Local Institution - 0087 Springdale, Arkansas, United States

Local Institution - 0080 Los Angeles, California, United States

View all 130 locations

View Trial Details

Neuroendocrine Tumors

Neuroendocrine Tumors trial results

Related conditions